Alexion Pharmaceuticals, Inc. (ALXN)

Check out top investors' recommendation for ALXN
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
167.64
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
100%/0%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. The company offers Soliris (eculizumab), a therapeutic product for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also conducts Phase IV clinical trails on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trails for its usage for the treatment of PNH pediatric trial, cold agglutinin disease, MPGN II/C3 nephropathy, hemolytic uremic syndrome, presensitized renal transplant, delayed kidney transplant graft function, ABO incompatible renal transplant, neuromyelitis optica, and myasthenia gravis. In addition, the company develops Asfotase alfa that is under Phase II clinical trail for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; and ALXN 1007, a novel humanized antibody for treating inflammatory disorders. Further, the company conducts preclinical trails on cPMP for treating metabolic disorders. It serves specialty distributors and specialty pharmacies, which supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, other healthcare providers, and distributors. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.
Sector:
Industry:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Simos Simeonidis Cowen And Company Buy   Sep 15, '17     161.00  Sep 15, '18  N/A 
Geoff Porges High Peaks Buy   Sep 13, '17     182.00  Sep 13, '18  N/A 
Alethia Young Deutsche Bank Securities Buy   Sep 12, '17     166.00  Sep 12, '18  N/A 
Ian Somaiya Piper Jaffray Buy   Sep 12, '17     173.00  Sep 12, '18  N/A 
Geoff Meacham JPMorgan Buy   Sep 12, '17     165.00  Sep 12, '18  N/A 
Stephen Willey Stifel Nicolaus & Company, Inc. Buy   Sep 12, '17     165.00  Sep 12, '18  N/A 
Alethia Young Deutsche Bank Securities Buy   Jul 28, '17     166.00  Jul 28, '18  N/A 
Geoff Porges High Peaks Buy   Jul 28, '17     170.00  Jul 28, '18  N/A 
Stephen Willey Stifel Nicolaus & Company, Inc. Buy   Jul 27, '17     157.00  Jul 27, '18  N/A 
Eric Schmidt Cowen And Company Buy   Jul 27, '17     180.00  Jul 27, '18  N/A 
Ian Somaiya Piper Jaffray Buy   Jul 21, '17     159.00  Jul 21, '18  N/A 
Christopher Marai Wedbush Securities Inc. Buy   Jul 17, '17     148.00  Jul 17, '18  N/A 
Matthew Harrison UBS Buy   Jul 11, '17     141.00  Jul 11, '18  N/A 
Stephen Willey Stifel Nicolaus & Company, Inc. Buy   Jun 23, '17     157.00  Jun 23, '18  N/A 
Matthew Harrison UBS Buy   May 25, '17     138.00  May 25, '18  N/A 
Christopher Raymond Robert W. Baird & Co., Inc. Buy   May 23, '17       May 23, '18  N/A 
Christopher Marai Wedbush Securities Inc. Buy   May 23, '17     148.00  May 23, '18  N/A 
Geoff Porges High Peaks Buy   May 23, '17       May 23, '18  N/A 
Eric Schmidt Cowen And Company Buy   Apr 28, '17     180.00  Apr 28, '18  N/A 
Howard Liang Leerink Swann Llc Buy   Mar 13, '17     208.00  Mar 13, '18  N/A 
< previous12345